The Pandol Laboratory at the Cedars-Sinai Pancreatic Research Program is dedicated to establishing and maintaining the leading international research area at Cedars-Sinai for advancing the prevention, early diagnosis and treatment of pancreatic diseases. Pancreatic cancer, pancreatitis and diabetes are disorders with life-threatening consequences for patients and broad-reaching repercussions for their family members and friends. Each year pancreatic cancer is diagnosed in 250,000 patients worldwide (more than 40,000 in the U.S.), and because only a limited number of patients are diagnosed early enough for successful surgical intervention, 225,000 die. To date, chemotherapy and radiotherapy are only partially and transiently effective. Pancreatitis is life threatening in its acute stage and causes immense and painful suffering in its chronic stages. In the U.S., the number of hospital admissions for pancreatitis is greater than for any other gastrointestinal disease. The Pancreatic Research Program is dedicated to discovering and characterizing the disease mechanisms for pancreatitis so that effective treatments can be developed.
Type 2 diabetes is a worldwide epidemic, with a prevalence reaching 10 percent in many populations. This is especially relevant to research in the Pandol Lab because diabetes underlies the risk of pancreatitis and pancreatic cancer, as well as other cancers and heart disease.
Basic and translational research efforts at the Pancreatic Research Program are designed to advance clinical care delivery to our patients.
The Pandol Laboratory is affiliated with the Pancreatic and Biliary Diseases Program and the Samuel Oschin Comprehensive Cancer Institute.
The Pandol Lab in the Cedars-Sinai Pancreatic Research Program is concentrating efforts to better understand the molecular mechanisms of pancreatic diseases and develop new prevention, diagnostic and effective treatments for these diseases. The Pancreatic Research Program's multidisciplinary team consists of molecular biologists, cell biologists, computational chemists, population scientists, clinical scientists and physicians, all working toward the common goal of enhanced treatments and outcomes for pancreatic cancer, pancreatitis and diabetes patients. Our research is focused on the following:
- Early diagnosis and disease prevention
- Signaling mechanisms, underlying risk factors and disease pathophysiology
- Development of novel therapeutics and enhanced treatments
- Human testing of new treatments
Collaborations & Resources
- Microscopy and Cell Culture
- Chemistry and Biochemistry
- Animal Physiology and Human Biomedical Sample Preparation
- Molecular Biology and Physical Biochemistry
- Specialized Reagents
- Access to Other Specialized Expertise and Equipment
- Computation and Structural Modeling
- Professional Societies
Meet Our Team
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Pandol Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Gukovskaya AS, Pandol SJ, Gukovsky I.
Curr Opin Gastroenterol. 2016 Jul 13.
Pham H, Hui H, Morvaridi S, Cai J, Zhang S, Tan J, Wu V, Levin N, Knudsen B, Goddard WA 3rd, Pandol SJ, Abrol R.
Biochem Biophys Res Commun. 2016 Jul 1;475(3):295-300.
Setiawan VW, Pandol SJ, Porcel J, Wilkens LR, Le Marchand L, Pike MC, Monroe KR.
Pancreas. 2016 Jul;45(6):819-825.
Contact the Pandol Lab
110 N. George Burns Rd.
Davis Building, Room 3096
Los Angeles, CA 90048